These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25141241)

  • 21. Acid-suppressive therapy with esomeprazole for relief of unexplained chest pain in primary care: a randomized, double-blind, placebo-controlled trial.
    Flook NW; Moayyedi P; Dent J; Talley NJ; Persson T; Karlson BW; Ruth M
    Am J Gastroenterol; 2013 Jan; 108(1):56-64. PubMed ID: 23147520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease.
    Bayerdörffer E; Bigard MA; Weiss W; Mearin F; Rodrigo L; Dominguez Muñoz JE; Grundling H; Persson T; Svedberg LE; Keeling N; Eklund S
    BMC Gastroenterol; 2016 Apr; 16():48. PubMed ID: 27080034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obesity does not affect treatment outcomes with proton pump inhibitors.
    Sharma P; Vakil N; Monyak JT; Silberg DG
    J Clin Gastroenterol; 2013 Sep; 47(8):672-7. PubMed ID: 23442835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.
    Fass R; Chey WD; Zakko SF; Andhivarothai N; Palmer RN; Perez MC; Atkinson SN
    Aliment Pharmacol Ther; 2009 Jun; 29(12):1261-72. PubMed ID: 19392864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial.
    Angiolillo DJ; Hwang C; Datto C; Desai B; Sostek M
    Clin Ther; 2011 Dec; 33(12):1883-93. PubMed ID: 22078153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Symptom-relieving effect of esomeprazole 40 mg daily in patients with heartburn.
    Johnsson F; Hatlebakk JG; Klintenberg AC; Román J
    Scand J Gastroenterol; 2003 Apr; 38(4):347-53. PubMed ID: 12739705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg.
    Eggleston A; Katelaris PH; Nandurkar S; Thorpe P; Holtmann G;
    Aliment Pharmacol Ther; 2009 May; 29(9):967-78. PubMed ID: 19210493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease.
    Dent J; Kahrilas PJ; Hatlebakk J; Vakil N; Denison H; Franzén S; Lundborg P
    Am J Gastroenterol; 2008 Jan; 103(1):20-6. PubMed ID: 18184117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
    Fass R; Inadomi J; Han C; Mody R; O'Neil J; Perez MC
    Clin Gastroenterol Hepatol; 2012 Mar; 10(3):247-53. PubMed ID: 22155561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study.
    Vakil NB; Huff FJ; Bian A; Jones DS; Stamler D
    Am J Gastroenterol; 2011 Aug; 106(8):1427-38. PubMed ID: 21519360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study.
    Labenz J; Armstrong D; Lauritsen K; Katelaris P; Schmidt S; Schütze K; Wallner G; Juergens H; Preiksaitis H; Keeling N; Nauclér E; Eklund S;
    Aliment Pharmacol Ther; 2005 Mar; 21(6):739-46. PubMed ID: 15771760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and tolerability of high-dose intravenous esomeprazole for prevention of peptic ulcer rebleeding.
    Kuipers EJ; Sung JJ; Barkun A; Mössner J; Jensen D; Stuart R; Lau JY; Ahlbom H; Lind T; Kilhamn J
    Adv Ther; 2011 Feb; 28(2):150-9. PubMed ID: 21181319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease.
    Kinoshita Y; Ashida K; Hongo M;
    Aliment Pharmacol Ther; 2011 Jan; 33(2):213-24. PubMed ID: 21083596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study.
    Labenz J; Armstrong D; Zetterstrand S; Eklund S; Leodolter A
    Aliment Pharmacol Ther; 2009 May; 29(9):959-66. PubMed ID: 19222417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
    Bytzer P; van Zanten SV; Mattsson H; Wernersson B
    Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis.
    Fennerty MB; Johanson JF; Hwang C; Sostek M
    Aliment Pharmacol Ther; 2005 Feb; 21(4):455-63. PubMed ID: 15709997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease - a double-blind, placebo-controlled, randomized study.
    Fass R; Delemos B; Nazareno L; Kao R; Xiang J; Lu Y
    Aliment Pharmacol Ther; 2010 May; 31(9):950-60. PubMed ID: 20132154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled "ENTER" trial.
    van Zanten SV; Armstrong D; Chiba N; Flook N; White RJ; Chakraborty B; Gasco A
    Am J Gastroenterol; 2006 Sep; 101(9):2096-106. PubMed ID: 16817845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Randomized, Double-blind, Active-Controlled, Multi-center Study of Ilaprazole in the Treatment of Reflux Esophagitis.
    Xue Y; Qin X; Zhou L; Lin S; Wang L; Hu H; Xia J
    Clin Drug Investig; 2016 Dec; 36(12):985-992. PubMed ID: 27605258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.
    Richter JE; Kahrilas PJ; Johanson J; Maton P; Breiter JR; Hwang C; Marino V; Hamelin B; Levine JG;
    Am J Gastroenterol; 2001 Mar; 96(3):656-65. PubMed ID: 11280530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.